한글목차

세계의 직장암 분자진단 시장 전망은 임상 진단, 약물 스크리닝, 조사 시장의 기회에 의해 유망합니다. 세계의 직장암 분자진단 시장의 2025-2031년 CAGR은 11.5를 나타낼 전망입니다. 이 시장의 주요 성장 촉진요인은 직장암 유병률 증가와 조기 검진 수요, 맞춤형 의약품 및 표적 치료 접근법의 확산입니다.

• Lucintel의 예측에서 유형별로 DNA 시퀀싱는 예측 기간 동안 가장 큰 부문입니다.
• 용도별로는 임상 진단이 가장 높은 성장을 이룰 전망입니다.
• 지역별로는 아시아태평양이 예측 기간 동안 가장 높은 성장을 보일 것으로 예측됩니다.

직장암 분자진단 시장의 새로운 동향

직장암 분자진단 시장은 진단 기술 혁신, 맞춤형 치료 옵션, 비침습적 검사 방법 발전 등 여러 신흥 동향을 가지고 있습니다. 이러한 동향은 시장의 전망을 형성하고 임상 결과를 개선하고 있습니다.

• 액체 생검 기술의 부상 : 액체 생검은 직장암 분자진단에 점점 더 많이 활용되고 있습니다. 이는 기존 조직 생검에 대한 비침습적 대안을 제공하여 혈액 샘플에서 종양 DNA를 검출할 수 있게 합니다. 이 기술은 조기 발견을 개선하고 치료 반응 모니터링에 도움을 주어 환자 관리를 향상시킵니다.
• 차세대 시퀀싱(NGS)의 발전 : NGS는 분자 진단의 핵심 기술로 자리 잡았으며, 직장암과 관련된 유전자 변이 및 개질된 유전체를 탐지할 수 있게 합니다. NGS는 포괄적인 유전체 프로파일링을 가능하게 하여 암의 조기 발견과 맞춤형 치료 전략 개발을 지원합니다.
• 맞춤형 의약품에 대한 주력 : 직장암 분자 진단 분야에서 맞춤형 의약품이 성장세를 보이고 있습니다. 유전자 변이를 식별함으로써 의료진은 개별 환자 프로필에 기반한 맞춤형 치료를 제공할 수 있습니다. 이 접근법은 환자가 가장 효과적인 치료를 받도록 보장하여 생존 가능성을 높이고 불필요한 부작용을 감축합니다.
• 진단에 인공지능(AI) 통합 : AI는 유전적, 조직병리학적, 영상 데이터를 포함한 대규모 환자 데이터 세트를 분석함으로써 직장암 분자 진단에서 상당한 역할을 수행하고 있습니다. AI 공구는 인간 임상의가 놓칠 수 있는 패턴을 탐지하여 진단 정확도를 향상시키고 더 정밀한 예후 정보를 제공합니다.
• 현장 진단(Point-of-Care Diagnostics)의 증가하는 채택 : 현장진단에 대한 관심이 증가하고 있으며, 이는 더 빠른 분자 시험과 신속한 결과를 가능하게 합니다. 이 동향은 중앙 집중식 진단 실험실 접근이 제한될 수 있는 개발도상국에서 특히 관련성이 높습니다. 현장진단 기술은 분자 진단을 보다 접근 가능하고 시기적절하게 만드는 데 기여하고 있습니다.

이러한 신흥 동향은 조기 발견, 더 높은 정확도, 덜 침습적인 방식으로 직장암 분자 진단을 변화시키고 있습니다. 이는 전 세계 환자들의 임상적 결과를 개선하고 직장암의 전반적인 예후를 향상시키며, 더욱 개인화된 치료 전략의 길을 열어주고 있습니다.

직장암 분자진단 시장의 최근 동향

진단 기술, 바이오마커, 치료 전략의 발전과 함께 직장암 분자진단은 급속한 발전을 이루고 있습니다. 이러한 발전은 진단 정확도를 향상시키고 개별 환자에게 맞춤화된 치료를 제공하는 능력을 향상시키고 있습니다.

• 소개 : 비침습적 진단 방법의 부상, 유전체 검사 접근성 향상, AI 기술 통합 등 여러 주요 발전이 직장암 분자 진단을 형성하고 있습니다. 이러한 발전은 직장암 분야의 진단 능력과 환자 치료를 개선하고 있습니다.
• 비침습적 검사 발전 : 액체 생검 및 대변 기반 DNA 검사 같은 비침습적 검사 방법이 빠르게 발전하고 있습니다.
• 개선된 유전체 프로파일링 기술 : 차세대 시퀀싱(NGS)을 활용한 유전체 프로파일링 기술이 발전하면서 직장암과 연관된 특정 돌연변이를 더 정확하게 식별할 수 있게 되었습니다. 이는 더 정밀한 진단과 맞춤형 치료법 개발로 이어져 환자의 치료 결과를 개선하고 있습니다.
• 진단 분야의 인공지능 : 인공지능이 직장암 분자 진단에 통합되면서 검출 정확도와 효율성이 모두 향상되고 있습니다. 인공지능은 유전체 데이터, 의료 기록, 영상 검사 결과를 분석하여 초기 직장암을 시사하는 패턴을 식별함으로써 더 빠른 개입과 더 나은 예후를 가능하게 합니다.
• 조기 발견을 위한 신흥 바이오마커 : 연구자들은 직장암에 특화된 새로운 바이오마커를 발견하고 있으며, 이는 조기 발견과 예후 예측을 개선하고 있습니다. 특정 유전자 변이 및 순환 종양 DNA와 같은 바이오마커는 가장 효과적인 치료 접근법을 결정하고 환자 진행 상황을 모니터링하는 데 도움이 될 수 있습니다.
• 맞춤형 의약품의 성장 : 직장암 진단 분야에서 맞춤형 의약품이 확대되고 있습니다. 환자의 유전적 프로필을 분석함으로써 의료진은 표적 치료를 포함한 가장 적합한 치료법을 선택할 수 있어, 기존 치료법의 부작용을 최소화하면서 환자 결과를 개선할 수 있습니다.

이러한 핵심 발전은 직장암의 분자 진단을 진전시켜 조기 발견을 더욱 효과적으로 하고 치료를 더욱 개인화하고 있습니다. 이러한 기술이 계속 발전함에 따라 환자 예후를 상당히 개선하고 전 세계 암 치료에 혁명을 기록할 잠재력을 지니고 있습니다.

목차

제1장 주요 요약

제2장 시장 개요

• 배경과 분류
• 공급망

제3장 시장 동향과 예측 분석

• 업계의 촉진요인과 과제
• PESTLE 분석
• 특허 분석
• 규제 환경

제4장 직장암 분자진단 시장 : 유형별

• 개요
• 유형별 : 매력 분석
• PCR : 동향과 예측(2019-2031년)
• FISH : 동향과 예측(2019-2031년)
• DNA 시퀀싱 : 동향과 예측(2019-2031년)
• 유전자 칩 : 동향과 예측(2019-2031년)

제5장 세계의 직장암 분자진단 시장 : 용도별

• 개요
• 용도별 : 매력 분석
• 임상 진단 : 동향과 예측(2019-2031년)
• 약물 스크리닝 : 동향과 예측(2019-2031년)
• 조사 : 동향과 예측(2019-2031년)

제6장 지역 분석

• 개요
• 지역별 : 세계의 직장암 분자진단 시장

제7장 북미의 직장암 분자진단 시장

• 개요
• 북미의 직장암 분자진단 시장(유형별)
• 북미의 직장암 분자진단 시장(용도별)
• 미국의 직장암 분자진단 시장
• 멕시코의 직장암 분자진단 시장
• 캐나다의 직장암 분자진단 시장

제8장 유럽의 직장암 분자진단 시장

• 개요
• 유럽의 직장암 분자진단 시장(유형별)
• 유럽의 직장암 분자진단 시장(용도별)
• 독일의 직장암 분자진단 시장
• 프랑스의 직장암 분자진단 시장
• 스페인의 직장암 분자진단 시장
• 이탈리아의 직장암 분자진단 시장
• 영국의 직장암 분자진단 시장

제9장 아시아태평양의 직장암 분자진단 시장

• 개요
• 아시아태평양의 직장암 분자진단 시장(유형별)
• 아시아태평양의 직장암 분자진단 시장(용도별)
• 일본의 직장암 분자진단 시장
• 인도의 직장암 분자진단 시장
• 중국의 직장암 분자진단 시장
• 한국의 직장암 분자진단 시장
• 인도네시아의 직장암 분자진단 시장

제10장 기타 지역의 직장암 분자진단 시장

• 개요
• 기타 지역의 직장암 분자진단 시장(유형별)
• 기타 지역의 직장암 분자진단 시장(용도별)
• 중동의 직장암 분자진단 시장
• 남미의 직장암 분자진단 시장
• 아프리카의 직장암 분자진단 시장

제11장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석
  • 경쟁 기업간 경쟁 관계
  • 구매자의 협상력
  • 공급기업의 협상력
  • 대체품의 위협
  • 신규 참가업체의 위협
• 시장 점유율 분석

제12장 기회와 전략 분석

• 밸류체인 분석
• 성장 기회 분석
  • 유형별 성장 기회
  • 용도별 성장 기회
• 세계의 직장암 분자진단 시장에 있어서의 새로운 동향
• 전략 분석
  • 신제품 개발
  • 인증 및 라이선싱
  • 합병, 인수, 계약, 제휴, 합작 사업

제13장 밸류체인 전체에 걸친 주요 기업의 기업 프로파일

• Competitive Analysis
• Kingmed
• Geneis
• Unitedgene
• Yin Feng Gene
• Inmedi
• Amoydx
• Genetronhealth

제14장 부록

• 도표 일람
• 표 목록
• 조사 방법
• 면책사항
• 저작권
• 약어와 기술 단위
• 당사에 대해
• 문의

영문목차

The future of the global molecular diagnosis of rectal cancer market looks promising with opportunities in the clinical diagnosis, drug screening, and research markets. The global molecular diagnosis of rectal cancer market is expected to grow with a CAGR of 11.5% from 2025 to 2031. The major drivers for this market are the rising prevalence of rectal cancer and demand for early detection and the growing adoption of personalized medicine and targeted treatment approaches.

• Lucintel forecasts that, within the type category, DNA sequencing will remain the largest segment over the forecast period.
• Within the application category, clinical diagnosis is expected to witness the highest growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Molecular Diagnosis of Rectal Cancer Market

The molecular diagnosis of rectal cancer market is witnessing several emerging trends, with innovations in diagnostic techniques, personalized treatment options, and advancements in non-invasive testing methods. These trends are shaping the market's future and improving clinical outcomes.

• Rise of Liquid Biopsy Technologies: Liquid biopsy is increasingly being used for the molecular diagnosis of rectal cancer. It offers a non-invasive alternative to traditional tissue biopsy, allowing for the detection of tumor DNA in blood samples. This technology improves early detection and helps in monitoring treatment responses, enabling better patient management.
• Advancements in Next-Generation Sequencing (NGS): NGS has become a cornerstone of molecular diagnostics, enabling the detection of genetic mutations and alterations associated with rectal cancer. NGS allows for comprehensive genomic profiling, which aids in the early identification of cancer and the development of personalized treatment strategies.
• Growing Focus on Personalized Medicine: Personalized medicine is gaining momentum in the molecular diagnosis of rectal cancer. By identifying genetic mutations, healthcare providers can tailor treatments based on individual patient profiles. This approach ensures that patients receive the most effective therapies, improving their chances of survival and reducing unnecessary side effects
• Integration of Artificial Intelligence (AI) in Diagnostics: AI is playing a significant role in the molecular diagnosis of rectal cancer by analyzing large sets of patient data, including genetic, histopathological, and imaging data. AI tools can detect patterns that human clinicians might miss, enhancing diagnostic accuracy and providing more precise prognostic information.
• Increased Adoption of Point-of-Care Diagnostics: There is a growing interest in point-of-care diagnostics, which allows for faster molecular testing and quicker results. This trend is particularly relevant in developing countries where access to centralized diagnostic laboratories may be limited. Point-of-care technologies are helping make molecular diagnosis more accessible and timely.

These emerging trends are transforming the molecular diagnosis of rectal cancer by making detection earlier, more accurate, and less invasive. They are paving the way for more personalized treatment strategies and improving clinical outcomes for patients worldwide, enhancing the overall prognosis for rectal cancer.

Recent Developments in the Molecular Diagnosis of Rectal Cancer Market

The molecular diagnosis of rectal cancer is undergoing rapid development with advancements in diagnostic techniques, biomarkers, and treatment strategies. These developments are enhancing diagnostic accuracy and the ability to tailor treatments to individual patients.

• Introduction: Several key developments are shaping the molecular diagnosis of rectal cancer, including the rise of non-invasive diagnostic methods, better access to genomic testing, and integration of AI technologies. These developments are improving diagnostic capabilities and patient care in the field of rectal cancer.
• Advancement of Non-Invasive Testing: Non-invasive testing methods such as liquid biopsy and stool-based DNA testing are rapidly advancing. These technologies allow for early detection of rectal cancer with minimal patient discomfort, paving the way for more widespread screening and monitoring options, especially in underserved populations.
• Improved Genomic Profiling Techniques: Genomic profiling is evolving with the use of next-generation sequencing (NGS) to better identify specific mutations linked to rectal cancer. This has led to more precise diagnoses and the development of personalized therapies, improving treatment outcomes for patients.
• Artificial Intelligence in Diagnostics: AI is being incorporated into molecular diagnostics for rectal cancer, improving both the accuracy and efficiency of detection. AI can analyze genomic data, medical records, and imaging results to identify patterns indicative of early-stage rectal cancer, enabling quicker interventions and better prognosis.
• Emerging Biomarkers for Early Detection: Researchers are identifying new biomarkers specific to rectal cancer, which are improving early detection and prognostication. Biomarkers such as specific genetic mutations and circulating tumor DNA can help in determining the most effective treatment approaches and monitoring patient progress.
• Growth of Personalized Medicine: Personalized medicine is expanding within rectal cancer diagnostics. By analyzing a patient's genetic profile, clinicians can choose the most appropriate treatments, including targeted therapies, improving patient outcomes while minimizing the side effects of traditional treatments.

These key developments are advancing the molecular diagnosis of rectal cancer, making early detection more effective and treatment more personalized. As these technologies continue to evolve, they hold the potential to significantly improve patient outcomes and revolutionize cancer care globally.

Strategic Growth Opportunities in the Molecular Diagnosis of Rectal Cancer Market

The global molecular diagnosis of rectal cancer market offers significant growth opportunities across various applications, driven by advancements in diagnostics and increasing demand for personalized medicine.

• Early Detection Screening Programs: Early detection is a key growth opportunity, especially as molecular diagnostics improve. Governments and healthcare organizations are increasingly implementing screening programs to detect rectal cancer at early stages, where treatment options are more effective. This market segment is expanding as molecular tests become more accessible and affordable.
• Personalized Treatment Plans: Personalized treatment strategies, informed by molecular diagnostics, offer a significant growth opportunity. By using genetic and biomarker profiling, clinicians can tailor therapies that target specific mutations, improving treatment efficacy and patient outcomes. This approach is particularly important in rectal cancer, where treatment response varies.
• Point-of-Care Diagnostics in Developing Markets: There is an opportunity to expand point-of-care molecular diagnostic tools in developing countries, where access to centralized healthcare may be limited. These tools enable quicker diagnosis, allowing for faster treatment initiation, which can significantly improve survival rates.
• Integration of AI for Faster Diagnosis: AI offers significant growth opportunities in the molecular diagnosis of rectal cancer, especially in data analysis. By integrating AI with molecular diagnostic tools, healthcare providers can achieve quicker and more accurate results, leading to faster interventions and better outcomes for patients.
• Expanding Liquid Biopsy Technologies: Liquid biopsy is rapidly becoming a preferred method for non-invasive testing. This technology offers the ability to detect tumor DNA in blood, facilitating early diagnosis, monitoring, and treatment response evaluation. The expansion of liquid biopsy technologies is expected to significantly boost the molecular diagnosis market.

The molecular diagnosis of rectal cancer market is ripe with growth opportunities, driven by advancements in early detection, personalized medicine, and AI integration. As these technologies evolve, they promise to revolutionize cancer care, improving patient outcomes and increasing access to timely treatment.

Molecular Diagnosis of Rectal Cancer Market Driver and Challenges

The molecular diagnosis of rectal cancer is influenced by various drivers such as technological advancements, increased awareness, and improved healthcare access. However, challenges related to cost, regulatory hurdles, and market penetration need to be addressed for sustained growth in this field.

The factors responsible for driving the molecular diagnosis of rectal cancer market include:

1. Technological Advancements in Diagnostics: The continuous development of advanced diagnostic technologies such as next-generation sequencing (NGS) and liquid biopsy is driving market growth. These innovations enable more accurate, less invasive, and earlier detection of rectal cancer, improving patient outcomes and increasing the demand for molecular diagnostic tools.

2. Growing Demand for Personalized Medicine: With the shift toward personalized medicine, there is an increasing demand for molecular diagnostics to guide treatment decisions. By identifying specific biomarkers and genetic mutations, healthcare providers can tailor treatments to the individual, improving efficacy and reducing side effects, thereby enhancing market growth.

3. Rising Awareness of Rectal Cancer: As awareness of rectal cancer and its risks rises globally, patients are more proactive about screening and diagnosis. This is leading to greater adoption of molecular diagnostic techniques, particularly in countries with developed healthcare systems.

4. Government and Healthcare Initiatives: Governments and healthcare organizations are promoting early detection and screening programs for rectal cancer. Increased funding and support for molecular diagnostics in these initiatives are helping expand access to cutting-edge diagnostic tools, contributing to market growth.

5. Improvement in Healthcare Access: As healthcare access improves in developing regions, the adoption of molecular diagnostics is expected to increase. This will drive market growth by enabling more widespread use of advanced diagnostic techniques, which were previously limited to wealthier countries.

Challenges in the molecular diagnosis of rectal cancer market are:

1. High Cost of Molecular Diagnostics: The high cost of advanced molecular diagnostic techniques is a major barrier to market growth, especially in low- and middle-income countries. The cost of technologies such as NGS and liquid biopsy needs to decrease to make these tools more accessible and affordable for a wider population.

2. Regulatory Challenges: Regulatory approvals for new diagnostic tests can be slow and challenging, particularly for new technologies like liquid biopsy. Navigating these regulatory hurdles can delay the widespread adoption of new diagnostic methods.

3. Limited Awareness and Accessibility in Rural Areas: Despite advancements in technology, there is limited access to molecular diagnostics in rural and underserved regions. Lack of infrastructure and awareness about the importance of early rectal cancer detection poses a challenge to the growth of the market.

Technological advancements, personalized medicine, and government support are key drivers of the molecular diagnosis of rectal cancer market. However, challenges like high costs, regulatory hurdles, and limited access in rural areas need to be addressed to ensure broader adoption of these life-saving diagnostic tools.

List of Molecular Diagnosis of Rectal Cancer Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies molecular diagnosis of rectal cancer companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the molecular diagnosis of rectal cancer companies profiled in this report include-

• Kingmed
• Geneis
• Unitedgene
• Yin Feng Gene
• Inmedi
• Amoydx
• Genetronhealth

Molecular Diagnosis of Rectal Cancer Market by Segment

The study includes a forecast for the global molecular diagnosis of rectal cancer market by type, application, and region.

Molecular Diagnosis of Rectal Cancer Market by Type [Value from 2019 to 2031]:

• PCR
• FISH
• DNA Sequencing
• Gene Chip

Molecular Diagnosis of Rectal Cancer Market by Application [Value from 2019 to 2031]:

• Clinical Diagnosis
• Drug Screening
• Research

Molecular Diagnosis of Rectal Cancer Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Molecular Diagnosis of Rectal Cancer Market

The global market for the molecular diagnosis of rectal cancer is evolving rapidly with advancements in genetic testing, biomarker discovery, and imaging technologies. These innovations are transforming early detection, prognosis assessment, and personalized treatment strategies for rectal cancer. Countries like the United States, China, Germany, India, and Japan are leading these developments, focusing on improving diagnostic accuracy and patient outcomes through cutting-edge molecular techniques.

• United States: In the United States, the molecular diagnosis of rectal cancer is benefiting from significant advancements in genomic testing and liquid biopsy technologies. Major institutions and companies are integrating next-generation sequencing (NGS) and artificial intelligence to enhance detection accuracy and predict patient responses to treatment. The U.S. market also sees increasing use of comprehensive genetic profiling to tailor personalized therapies, helping in better treatment planning and outcome prediction for patients with rectal cancer.
• China: China is experiencing rapid growth in the molecular diagnosis of rectal cancer, largely driven by the country's investment in advanced healthcare technologies and research. The Chinese market is seeing increased adoption of molecular diagnostic tools like PCR, NGS, and liquid biopsy, enabling earlier and more accurate detection of rectal cancer. Additionally, there is a focus on developing cost-effective solutions to make advanced diagnostics accessible across urban and rural areas, aiming to improve early diagnosis and survival rates.
• Germany: In Germany, the molecular diagnosis of rectal cancer is advancing with the integration of precision medicine and genetic testing into clinical practice. Key advancements include the use of molecular markers to guide treatment decisions and predict patient outcomes. Germany's focus on personalized healthcare is driving the adoption of liquid biopsy and genetic profiling, improving early detection and enabling more effective management of rectal cancer. Germany is also a hub for research into novel biomarkers that could further refine diagnostic accuracy.
• India: India is focusing on improving the molecular diagnosis of rectal cancer through increased access to affordable genomic testing and advanced imaging technologies. Companies and hospitals are expanding their use of NGS and PCR for early detection and monitoring of rectal cancer. India's healthcare system is embracing molecular diagnostics to enhance personalized treatment plans and improve patient outcomes, although challenges remain in accessibility and cost-effectiveness in rural areas.
• Japan: Japan has made significant progress in the molecular diagnosis of rectal cancer, with a strong emphasis on advanced diagnostic technologies like NGS and liquid biopsy. The Japanese healthcare system is increasingly adopting molecular profiling for personalized treatment regimens, including targeted therapies. Research institutions are also investigating novel biomarkers to improve the detection of early-stage rectal cancer, aiming to enhance early intervention and improve survival rates through timely diagnosis.

Features of the Global Molecular Diagnosis of Rectal Cancer Market

• Market Size Estimates: Molecular diagnosis of rectal cancer market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Molecular diagnosis of rectal cancer market size by type, application, and region in terms of value ($B).
• Regional Analysis: Molecular diagnosis of rectal cancer market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the molecular diagnosis of rectal cancer market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the molecular diagnosis of rectal cancer market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the molecular diagnosis of rectal cancer market by type (PCR, FISH, DNA sequencing, and gene chip), application (clinical diagnosis, drug screening, and research), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Molecular Diagnosis of Rectal Cancer Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 PCR: Trends and Forecast (2019-2031)
• 4.4 FISH: Trends and Forecast (2019-2031)
• 4.5 DNA Sequencing: Trends and Forecast (2019-2031)
• 4.6 Gene Chip: Trends and Forecast (2019-2031)

5. Global Molecular Diagnosis of Rectal Cancer Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Clinical Diagnosis: Trends and Forecast (2019-2031)
• 5.4 Drug Screening: Trends and Forecast (2019-2031)
• 5.5 Research: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Molecular Diagnosis of Rectal Cancer Market by Region

7. North American Molecular Diagnosis of Rectal Cancer Market

• 7.1 Overview
• 7.2 North American Molecular Diagnosis of Rectal Cancer Market by type
• 7.3 North American Molecular Diagnosis of Rectal Cancer Market by application
• 7.4 United States Molecular Diagnosis of Rectal Cancer Market
• 7.5 Mexican Molecular Diagnosis of Rectal Cancer Market
• 7.6 Canadian Molecular Diagnosis of Rectal Cancer Market

8. European Molecular Diagnosis of Rectal Cancer Market

• 8.1 Overview
• 8.2 European Molecular Diagnosis of Rectal Cancer Market by type
• 8.3 European Molecular Diagnosis of Rectal Cancer Market by application
• 8.4 German Molecular Diagnosis of Rectal Cancer Market
• 8.5 French Molecular Diagnosis of Rectal Cancer Market
• 8.6 Spanish Molecular Diagnosis of Rectal Cancer Market
• 8.7 Italian Molecular Diagnosis of Rectal Cancer Market
• 8.8 United Kingdom Molecular Diagnosis of Rectal Cancer Market

9. APAC Molecular Diagnosis of Rectal Cancer Market

• 9.1 Overview
• 9.2 APAC Molecular Diagnosis of Rectal Cancer Market by type
• 9.3 APAC Molecular Diagnosis of Rectal Cancer Market by application
• 9.4 Japanese Molecular Diagnosis of Rectal Cancer Market
• 9.5 Indian Molecular Diagnosis of Rectal Cancer Market
• 9.6 Chinese Molecular Diagnosis of Rectal Cancer Market
• 9.7 South Korean Molecular Diagnosis of Rectal Cancer Market
• 9.8 Indonesian Molecular Diagnosis of Rectal Cancer Market

10. ROW Molecular Diagnosis of Rectal Cancer Market

• 10.1 Overview
• 10.2 ROW Molecular Diagnosis of Rectal Cancer Market by type
• 10.3 ROW Molecular Diagnosis of Rectal Cancer Market by application
• 10.4 Middle Eastern Molecular Diagnosis of Rectal Cancer Market
• 10.5 South American Molecular Diagnosis of Rectal Cancer Market
• 10.6 African Molecular Diagnosis of Rectal Cancer Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Type
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global Molecular Diagnosis of Rectal Cancer Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 Kingmed
  • Company Overview
  • Molecular Diagnosis of Rectal Cancer Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Geneis
  • Company Overview
  • Molecular Diagnosis of Rectal Cancer Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Unitedgene
  • Company Overview
  • Molecular Diagnosis of Rectal Cancer Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Yin Feng Gene
  • Company Overview
  • Molecular Diagnosis of Rectal Cancer Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Inmedi
  • Company Overview
  • Molecular Diagnosis of Rectal Cancer Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 Amoydx
  • Company Overview
  • Molecular Diagnosis of Rectal Cancer Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 Genetronhealth
  • Company Overview
  • Molecular Diagnosis of Rectal Cancer Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us